Medgend Icon







discontinued


Bromocriptine Mesylate FDA Approved Drugs

BROMOCRIPTINE MESYLATE [Bromocriptine MesylateC32H40BrN5O5CH4O3S]
RX
-
eq 2.5mg base (oral tablet)
eq 5mg base (oral capsule)
MylanSep 24, 2004
Paddock LlcOct 1, 2008
Sandoz IncJan 13, 1998
Zydus Pharms Usa IncJul 30, 2008
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

CYCLOSET [Bromocriptine MesylateC32H40BrN5O5CH4O3S]
RX
-
eq 0.8mg base (oral tablet)
VeroscienceMay 5, 2009
  • Administration once daily within two hours after waking in the morning for improvement of glycemic control in a type 2 diabetes patient.
  • Improvement of glycemic control in individuals with type 2 diabetes.
  • Improvements of glycemic control in individuals with type 2 diabetes who have one or more specified cardiovascular risk factors.
  • Treatment of type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue wherein the combined therapeutic effect is greater than the additive effect of administering each agent alone.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

PARLODEL [Bromocriptine MesylateC32H40BrN5O5CH4O3S]
RX
-
eq 2.5mg base (oral tablet)
eq 5mg base (oral capsule)
Us Pharms Holdings IApproved Prior To Jan 1, 1982
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.